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Sir,
We read with great interest the article by Perez et al.
(2018) on the emerging condition of intellectual disability
caused by biallelic pathogenic variants in RSRC1 (arginine
and serine rich coiled-coil 1). Previous genome wide associ-
ation studies (GWAS) by Potkin et al. (2009, 2010) had
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suggested a possible involvement of RSRC1 in non-syn-
dromic intellectual disability and gene regulatory networks
in schizophrenia. However, the results of these studies
remained elusive and were not confirmed by a subsequent
GWAS study by Schizophrenia Working Group of the
Psychiatric Genomics Consortium (2014). Meanwhile,
Berndt et al. (2013) identified RSRC1 as a new locus influ-
encing height through a genome-wide meta-analysis. The
first family in which a homozygous RSRC1 variant clearly
segregated with non-syndromic intellectual disability was
only recently reported by Maddirevula et al. (2018). A pos-
sible role of RSRC1 in major depressive disorder has been
further suggested by a meta-analysis on three large GWAS
performed by Li et al. (2018).
Serine and arginine-rich (SR) proteins are evolutionary con-
served co-regulators of constitutive and alternative pre-
mRNA splicing. The longest RSRC1 transcript
(NM_001271838.1) includes 10 exons (Fig. 1A) and encodes
a 334-amino-acid SR-related protein of 53 kDa (SRrp53)
(Fig. 1B), localized to the nuclear speckled domain.
Interacting with other splicing regulators, RSRC1 plays a rele-
vant role in the second step of pre-mRNA splicing. In add-
ition, it could be involved in post-splicing mRNA processing,
shuttling between the nucleus and cytoplasm (Cazalla et al.,
2005). RSRC1 further promotes PIAS1-mediated
SUMOylation of the pleiotropic transcription factor oestrogen
receptor b (ERb), acting as transcriptional regulator (Chen
et al., 2015).
The involvement of RSRC1 in cancer was first suggested
by the identification of the recurrent PTPLB-RSRC1 in-
frame gene fusion in nasopharyngeal carcinoma by Valouev
et al. (2014). Teplyuk et al. (2016) showed that RSRC1 is a
target gene of the microRNA-10b (miR-10b), an oncogenic
microRNA that is highly expressed in glioblastoma and rep-
resents a candidate for the development of targeted thera-
pies. More recently, several studies have implicated RSRC1
in cancer predisposition and progression. The RSRC1 in-
tronic polymorphism rs6441201 G4A has been associated
with neuroblastoma susceptibility (McDaniel et al., 2017;
Tang et al., 2018). A possible role of RSRC1 in non-small-
cell lung cancer tumorigenesis and progression has been
hypothesized based on the data from RNA sequencing data
of tumour-educated platelets (Sheng et al., 2018). RSRC1
has been also shown to suppress gastric cancer cell prolifer-
ation and migration through the regulation of PTEN expres-
sion, acting as tumour suppressor (Yu et al., 2019).
The first RSRC1 pathogenic variant segregating with intel-
lectual disability was reported by Maddirevula et al. (2018)
in three affected siblings from a consanguineous Malaysian
family (Supplementary Table 3). The homozygous truncating
variant c.268C4T (p.Arg90*) (NM_001271838.1) resulted
in a full loss of function, causing the natural knockout of
the gene. All the reported patients showed developmental
delay and variable degree of intellectual disability. One sub-
ject also suffered from febrile seizures. Brain MRI was nor-
mal in the 10-year-old male (Patient 1), whereas temporal
lobe atrophy was found in his 4-year-old brother (Patient 2).
No distinctive neurological features or facial dysmorphism
were observed. More recently, Perez et al. (2018) reported
five further individuals from consanguineous Bedouin kin-
dred with early developmental delay, intellectual disability,
hypotonia, behavioural abnormalities, and mild facial dys-
morphic features. Brain MRI was normal (Supplementary
Table 3). Exome sequencing revealed the homozygous
c.205C4T (p.Arg69*) in RSRC1 (NM_001271838.1) in all
patients, a nonsense variant leading to nonsense-mediated
mRNA decay. RSRC1 knock-down SH-SY5Y cells showed
impaired alternative splicing. Specific differential expression
of genes associated with intellectual disability, hypotonia,
schizophrenia, and dementia was also observed, supporting
the pivotal role of RSRC1 in transcriptional regulation
(Perez et al., 2018).
We report 17 additional subjects from seven consanguin-
eous families with intellectual disability, behavioural abnor-
malities, and facial dysmorphism, harbouring homozygous
RSRC1 loss-of-function variants (Table 1 and Supplementary
Table 1). The families were of different ancestries (European/
Middle Eastern, Saudi, Egyptian, Old Order Amish,
Pakistani, and Persian) (Supplementary Fig. 1). The collabor-
ation among the involved study centres was managed
through GeneMatcher (Sobreira et al., 2015). After informed
consent was obtained from the parents, photographic mater-
ial was collected and genetic testing through exome sequenc-
ing was performed. Genetic methods are provided in detail in
the Supplementary material. Trio-exome sequencing was con-
ducted in Patient 10, the family quartet was sequenced for
Patients 8 and 9, and proband-exome sequencing was per-
formed in all the remaining individuals, followed by variants
validation through Sanger sequencing. No relevant single nu-
cleotide variant was identified in the siblings of Amish ances-
try (Patients 1–4), who were further studied through
comparative genomic hybridization (CGH) array. Five
RSRC1 sequence variants (including an intragenic duplica-
tion) and two partial deletions were identified.
In all the enrolled subjects, global psychomotor develop-
mental delay and mild-to-moderate intellectual disability
were observed. Twelve patients were diagnosed with vari-
able behavioural disorders (Table 1 and Supplementary
Table 1). Neurological examination revealed generalized
hypotonia in all patients and five of them had a history of
hypotonia at birth. Decreased deep tendon reflexes were
found in six patients (35%). Five patients showed gait
ataxia, which was associated with bradykinesia in Patient
11. Truncal ataxia was observed in Patient 10. Seizures
occurred in six individuals (35%), including four cases of fe-
brile seizures. Afebrile generalized tonic-clonic seizures in
addition to febrile seizures were observed in Patients 7, 12,
and 13. Patient 10 experienced three episodes of generalized
tonic-clonic seizures before becoming seizure-free. His EEG
showed occasional epileptiform discharges in the centrofron-
tal and in the left parietocentral regions during sleep. No re-
current epileptic phenotype or peculiar EEG features were
recognizable in our cohort. Psychomotor regression was not
observed in any case. The most common dysmorphic
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Figure 1 Genetic findings and clinical pictures of RSRC1 patients. (A) Schematic diagram of the longer RSRC1 transcript
(NM_001271838.1) consisting of 2597 nucleotides in 10 exons. The deletions encompassing exons 2 and 9–10 are represented by diagonal green
lines. Single nucleotide variants are shown in red (previously reported patients) or in green (this study). (B) The RSRC1 protein
(NP_001258767.1) consists of 334 amino acids encompassing an RS domain rich in arginine (R) and serine (S) that mediates the interactions with
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features were deep-set eyes, broad nasal base, and ogival
palate (Fig. 1C). Associated congenital anomalies were ex-
tremely variable, ranging from simple pes planus to redun-
dant skin. Other isolated clinical features included mitral
valve prolapse, recurrent respiratory infections in the first
year of life, and tracheomalacia. When available, brain MRI
did not reveal any distinctive finding. Non-specific mild cere-
bral atrophy was observed in Patients 5 and 6, whereas en-
largement of subarachnoid spaces was found in Patients 2
and 3. Delayed myelination, dysmorphic lateral ventricles,
and unilateral focal polymicrogyria were observed in Patient
10.
In our cohort, we identified homozygous RSRC1 variants
or deletions leading to loss of function (Table 1 and
Supplementary Table 1). Variants’ nomenclatures are given
with reference to the RSRC1 transcript NM_001271838.1.
The four Amish siblings (Patients 1–4) carried an 81-kb dele-
tion encompassing exons 9–10 of RSRC1 and the entire
MLF1 gene. Although MLF1 is involved in haematopoiesis
and leukemogenesis, a possible pathogenic role for this gene
in some of the dysmorphic features and congenital anomalies
in the Amish patients cannot be excluded (Yoneda-Kato
et al., 1996; Nakamae et al., 2017). A second 500-bp dele-
tion involving exon 2 of RSRC1 was identified in the sib-
lings from the Pakistani family (Patients 8 and 9). Both these
rearrangements are novel and are not reported in ClinVar
and DECIPHER databases (Supplementary Table 1). The
three patients from the second Pakistani family (Patients
12–14) carried the splicing variant c.532-1G4A. This
amino acid change is predicted to cause aberrant splicing
through the alteration of the splice acceptor site at exon 6
of RSRC1 (Supplementary Table 3). In the remaining fami-
lies, homozygous stop-gain or start-loss variants were iden-
tified. The 16-year-old female of European ancestry
(Patient 11) harboured the intragenic duplication
c.441_447dupAGAAAAG (p.Glu150Argfs*6). The stop-
gain variants c.784C4T (p.Gln262*) and c.250C4T
(p.Arg84*) were identified in the siblings from the Persian
(Patients 5–7) and Middle East (Patient 10) families, re-
spectively. In the Egyptian family (Patients 15–17), the
variant c.3G4T (p.Met1?) causing a start loss and leading
to full loss of function (null variant) was found.
All the variants fully segregated with the phenotype and
were not found in the most common genome databases,
including the Genome Aggregation Database (gnomAD),
Iranome, Greater Middle East Variome Project (GME
Variome), and our database of 10 000 in-house control
exomes. The only exception was the splicing variant c.532-
1G4A, which was observed in heterozygous state in 3 of
166 052 in gnomAD (allele frequency 0.00001806).
Furthermore, the start loss variant affecting the same nucleo-
tide of the c.3G4T (p.Met1?) variant observed in our
Egyptian family is reported in heterozygous state in
gnomAD (genomes allele frequency 0.00003186). However,
neither variant has been reported in homozygous state in
healthy individuals. The analysis of sequence conservation
through Genomic Evolutionary Rate Profiling (GERP) score
revealed good conservation of the affected residues and in
silico prediction analysis through CADD score calculation
revealed high-deleterious scores (Supplementary Table 3).
All variants were predicted to be damaging or likely
damaging by several bioinformatic tools (e.g. SIFT,
MutationTaster, and Human Splice Finder) and were classi-
fied as pathogenic (class 5) or likely pathogenic (class 4)
according to the American College of Medical Genetics and
Genomics (ACMG) guidelines (Richards et al., 2015).
This study supports the idea that RSRC1 pathogenic var-
iants cause a non-syndromic disorder characterized by mild-
to-moderate intellectual disability, generalized hypotonia, and
variable neurological and behavioural features (Fig. 1D).
Despite a few minor dysmorphic features being observed (es-
pecially deep-set eyes and broad nasal base), a consistent re-
current facial gestalt could not be recognized. Furthermore,
the extremely variable associated non-neurological features
were not suggestive of a syndromic condition. Even though
seizures are common in RSRC1 patients, most of them only
Figure 1 Continued
other RS-rich proteins involved in splicing regulation (SF2/ASF and U2AF35) and a coiled coil domain required for RSRC1/ERb interaction as well
as the enhancement of ERb SUMOylation. The residues K196 and K 230 are necessary for RSRC1 SUMOylation by SUMO1 and the E3 ligases
PIAS1 and PIAS3. Pathogenic amino acid changes reported in previous papers and identified in this study are shown in red and green, respectively.
(C) Sequential pictures from selected patients. Patients from the Amish family (Patients 1–3) show prominent forehead, deep set eyes, depressed
nasal bridge, protruding ears, and overbite with drooling. Redundant skin is evident in Patient 1. The Persian patient (Patient 7) shows straight
eyebrows with mild synophrys, deep set eyes, and protruding ears. In the first Pakistani family (Patients 8 and 9) dysmorphic features include
straight eyebrows with mild medial flaring, deep set eyes, wide nasal base, short philtrum, uplifted earlobes, and prominent chin. Subjects from
the second Pakistani family (Patients 12–14) also show straight eyebrows with mild synophrys and deep set eyes, in addition to protruding ears
with uplifted lobes (Patient 14). Patients from the Egyptian family (Patients 15–17) show thick eyebrows with medial sparing, deep set eyes, and
prominent columella. (D) Graphic illustrations of the most common clinical findings in RSRC1 patients in our cohort: the bar graph shows the
percent distribution of the cardinal features of RSRC1-related intellectual disability, with the grey lines representing not available data; the pie
charts show the percentage distribution of developmental delay/intellectual disability and the different behavioural abnormalities observed in
RSRC1 patients. Gene transcript and protein details available at: https://www.ensembl.org (RSRC1-215, transcript ID ENST00000611884.5),
https://www.nextprot.org (NX_Q96IZ7), https://www.uniprot.org (Q96IZ7), https://www.proteomicsdb.org (Q96IZ7). ADHD = attention def-
icit hyperactivity disorder; ASD = autism spectrum disorder; DD = developmental delay; ID = intellectual disability; N/A = not available; Pt =
patient; SCT = sluggish cognitive tempo; TT = temper tantrums.
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suffer from febrile seizures, lacking a distinctive epileptic
phenotype. Definite epileptic seizures were only diagnosed in
Patient 12 and in a case reported by Perez et al. (2018).
This patient suffered from focal seizures with impaired
awareness occasionally progressing to tonic-clonic and
was treated with valproic acid. Behavioural abnormalities
are frequent, although extremely variable and ranging
from attention deficit hyperactivity disorder (ADHD) to
autism spectrum disorder (ASD) (Fig. 1D). Besides the
non-specific neuroradiological abnormalities observed in
our patients, bilateral symmetric temporal lobe atrophy
has been described in a single case by Maddirevula et al.
(2018). Even though further neuroimaging studies will be
necessary, the limited data available support the lack of a
peculiar neuroradiological phenotype. According to these
observations, biallelic RSRC1 variants should be consid-
ered the cause of a non-syndromic intellectual disability
mainly associated with generalized hypotonia and behav-
ioural disturbances. Facial dysmorphism and other minor
clinical features have limited diagnostic relevance, likewise
neuroimaging is of limited value.
Thanks to the remarkable advances in gene discovery
achieved through exome sequencing, the large group of
known genes causing non-syndromic intellectual disability is
rapidly expanding with relevant impact on diagnosis and pa-
tient management. Our findings support the pathogenic role
of biallelic loss-of-function RSRC1 variants in autosomal re-
cessive intellectual disability, in addition to contributing to
the phenotypic delineation of this emerging condition. Global
developmental delay, mild-to-moderate intellectual disability,
behavioural abnormalities, and generalized hypotonia repre-
sent the cardinal features of RSRC1-related intellectual dis-
ability. Other neurological features may be less frequently
observed, especially hyporeflexia and febrile seizures. Further
studies will help clarify the possible role of neuroimaging in
the diagnostic process. In conclusion, we suggest that the in-
volvement of RSRC1 should be considered in the differential
diagnosis in intellectually disabled children with hypotonia
and behavioural disturbances, and that RSRC1 should be
included in next generation sequencing (NGS) panels for in-
tellectual disability.
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